Brand Name
Nemluvio
Generic Name
Nemolizumab-Ilto
View Brand Information FDA approval date: August 13, 2024
Classification: Interleukin-31 Receptor alpha Antagonist
Form: Injection
What is Nemluvio (Nemolizumab-Ilto)?
NEMLUVIO is an interleukin-31 receptor antagonist indicated for: Prurigo Nodularis The treatment of adults with prurigo nodularis.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment